Avalo Therapeutics
AVTX
26 hedge funds and large institutions have $16M invested in Avalo Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
37% more funds holding
Funds holding: 19 → 26 (+7)
0.04% more ownership
Funds ownership: 0.25% → 0.29% (+0.04%)
43% less capital invested
Capital invested by funds: $28M → $16M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$3.28M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.97M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.56M |
| 4 |
AC
Armistice Capital
New York
|
+$1.48M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$79K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$4.73K |
| 5 |
Goldman Sachs
New York
|
-$3.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $277 | – | – | – |
|
|
MAM
27
Meeder Asset Management
Dublin,
Ohio
| $109 | -$4.73K | -6 | Closed |
|
|
NFSG
28
Newbridge Financial Services Group
Boca Raton,
Florida
| $18 | – | – | – |
|
29
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $10 | – | – | – |
|
|
KTC
30
Kistler-Tiffany Companies
Berwyn,
Pennsylvania
| $4 | – | – | – |
|
|
PA
31
Parallel Advisors
San Francisco,
California
| $2 | – | – | – |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$95K | -78 | Closed |
|
|
33
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$79K | -65 | Closed |
|
|
CA
34
Clearstead Advisors
Cleveland,
Ohio
| – | -$136 | – | – |
|
35
Fidelity Investments
Boston,
Massachusetts
| – | -$66 | – | – |
|
AVTX Hedge Fund Activity: Q1 2023 in Review
26 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2023, worth a combined $16M — down 43% from $28M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVTX positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $3.28M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $95K sold.
- 26 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2023, up from 19 in Q4 2022.
- Funds reported $16M of Avalo Therapeutics stock for Q1 2023, down 43% quarter-over-quarter.
- 10 funds opened new Avalo Therapeutics positions in Q1 2023 and 3 closed out, a net change of +7 holders.
- The largest Avalo Therapeutics buyer in Q1 2023 was VR Adviser, an estimated $3.28M added.
- The largest Avalo Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $95K sold.
Based on aggregated 13F filings for Q1 2023.